Response Genetics Buys Proprietary FDA-Cleared, Medicare-Reimbursed Test, All Associated Assets for Difficult to Diagnose Solid Tumors

Response Genetics, Inc. (Nasdaq: RGDX ), a company focused on the development and sale of molecular diagnostic tests for cancer, today announced the acquisition of all of the key assets of Pathwork Diagnostics, including its FDA-cleared, Medicare-reimbursed test for the diagnosis of metastatic, poorly differentiated and undifferentiated cancer. Terms of the deal include a